MedPath

Urovant Sciences GmbH

🇨🇭Switzerland
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

12

Active:0
Completed:9

Trial Phases

3 Phases

Phase 1:2
Phase 2:4
Phase 3:4

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials

Phase 2
4 (36.4%)
Phase 3
4 (36.4%)
Phase 1
2 (18.2%)
phase_2_3
1 (9.1%)

A Study of Vibegron in Pediatric Participants 2 Years to Less Than (<) 18 Years of Age With NDO and on CIC

Phase 2
Recruiting
Conditions
Neurogenic Detrusor Overactivity
Interventions
First Posted Date
2022-08-08
Last Posted Date
2024-07-03
Lead Sponsor
Urovant Sciences GmbH
Target Recruit Count
85
Registration Number
NCT05491525
Locations
🇺🇸

Children's Hospital of Orange County, Orange, California, United States

🇺🇸

Nemours Childrens Health, Jacksonville, Jacksonville, Florida, United States

🇺🇸

Wichita Urology Group, Wichita, Kansas, United States

and more 3 locations

Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)

Completed
Conditions
Overactive Bladder
Interventions
First Posted Date
2021-10-05
Last Posted Date
2024-12-27
Lead Sponsor
Urovant Sciences GmbH
Target Recruit Count
403
Registration Number
NCT05067478
Locations
🇺🇸

Urology Centers of Alabama, Homewood, Alabama, United States

🇺🇸

43rd Medical Associates, Phoenix, Arizona, United States

🇺🇸

Fiel Family and Sports Medicine, PC, Tempe, Arizona, United States

and more 60 locations

URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence

Phase 2
Completed
Conditions
Overactive Bladder With Urge Urinary Incontinence
Interventions
Drug: Placebo
First Posted Date
2019-12-26
Last Posted Date
2023-04-20
Lead Sponsor
Urovant Sciences GmbH
Target Recruit Count
80
Registration Number
NCT04211831
Locations
🇺🇸

Coastal Clinical Research Inc, Mobile, Alabama, United States

🇺🇸

Urological Associates of Southern Arizona, Tucson, Arizona, United States

🇺🇸

Orange County Urology Associates, Laguna Hills, California, United States

and more 17 locations

Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia

Phase 3
Completed
Conditions
Overactive Bladder
Interventions
First Posted Date
2019-09-25
Last Posted Date
2024-08-21
Lead Sponsor
Urovant Sciences GmbH
Target Recruit Count
276
Registration Number
NCT04103450
Locations
🇺🇸

Private Practice, Las Vegas, Nevada, United States

🇺🇸

Clinical Trials Research, Lincoln, California, United States

🇺🇸

American Institute of Research, Los Angeles, California, United States

and more 31 locations

Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

Phase 3
Completed
Conditions
Overactive Bladder
Interventions
Drug: Placebo
First Posted Date
2019-04-03
Last Posted Date
2024-08-07
Lead Sponsor
Urovant Sciences GmbH
Target Recruit Count
1105
Registration Number
NCT03902080
Locations
🇺🇸

Urology Centers of Alabama, Homewood, Alabama, United States

🇨🇦

Private Practice, Brampton, Ontario, Canada

🇺🇸

Coastal Clinical Research, Inc., Mobile, Alabama, United States

and more 132 locations
  • Prev
  • 1
  • 2
  • 3
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath